The Role of EMT-Related lncRNAs in Ovarian Cancer

Ovarian cancer (OC) is one of the deadliest cancers worldwide; late diagnosis and drug resistance are two major factors often responsible for high morbidity and treatment failure. Epithelial-to-mesenchymal transition (EMT) is a dynamic process that has been closely linked with cancer. Long non-codin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-06, Vol.24 (12), p.10079
Main Authors: Lampropoulou, Dimitra Ioanna, Papadimitriou, Marios, Papadimitriou, Christos, Filippou, Dimitrios, Kourlaba, Georgia, Aravantinos, Gerasimos, Gazouli, Maria
Format: Article
Language:English
Subjects:
Biomarkers
Cells
Drug resistance
Epigenetics
Fibroblasts
Genotype & phenotype
Growth factors
Health aspects
Immune system
Malignancy
Medical prognosis
Metastasis
MicroRNAs
Morbidity
Non-coding RNA
Ovarian cancer
Physiology
Resistance factors
Review
Stem cells
Therapeutic targets
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer (OC) is one of the deadliest cancers worldwide; late diagnosis and drug resistance are two major factors often responsible for high morbidity and treatment failure. Epithelial-to-mesenchymal transition (EMT) is a dynamic process that has been closely linked with cancer. Long non-coding RNAs (lncRNAs) have been also associated with several cancer-related mechanisms, including EMT. We conducted a literature search in the PubMed database in order to sum up and discuss the role of lncRNAs in regulating OC-related EMT and their underlying mechanisms. Seventy (70) original research articles were identified, as of 23 April 2023. Our review concluded that the dysregulation of lncRNAs is highly associated with EMT-mediated OC progression. A comprehensive understanding of lncRNAs' mechanisms in OC will help in identifying novel and sensitive biomarkers and therapeutic targets for this malignancy.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241210079